BSMD-Biosphere | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
BSMD-Biosphere

An SI Board Since August 1999

Posts	SubjectMarks	Bans
5	0	0

Emcee: ruey220	Type: Unmoderated

Introduction Compact

BioSphere Medical Releases its First Results

MARLBOROUGH, Mass.--(BUSINESS WIRE)--July 30, 1999--BioSphere Medical, Inc. (NASDAQ:BSMD - news)
announced today results of the second quarter of 1999.

For the three months ended June 30, 1999, BioSphere Medical recorded net revenues of $713,000 and a net loss from continuing operations of $1,025,000 or
$0.12 per share. In the comparable period of 1998, net revenues were $47,000 with a net loss from continuing operations of $211,000.

For the six months ended June 30, 1999, BioSphere Medical reported net revenues of $993,000 and a net loss from continuing operations of $1,564,000 or $0.18
per share, compared with net revenues of $117,000, and a net loss from continuing operations of $436,000, or $0.05 per share, for the same period in 1998.

In releasing these results, Mr. John Carnuccio, the Company's President and CEO said: ''This was the first quarter in which we conducted business as a newly
created medical device company, BioSphere Medical, Inc. With the sale of the BioSepra chromatography business in May, we established an entirely new business
strategy and management team, focused on microspheres for medical applications.

It is essential that the comparative results for both the quarter and the half-year be considered in light of these changes. While our results have been restated to
include only our new business, they do not reflect the impact of promotional efforts the Company expects to launch after FDA approval is obtained to market our
first product in the U.S. Embosphere microspheres are currently CE Mark approved in Europe. In May 1999, we filed a 510(k) for approval in the U.S.

''We believe that microspheres are a broad technology platform with potential applications in embolotherapy, bulking, drug delivery, and tissue repair. Our initial
focus will be on embolization of arteriovenous malformations, hypervascularized tumors including uterine fibroids, and other vascular defects. This application of our
technology alone addresses a growing worldwide market in neurological and vascular interventions with sales potential in excess of $500 million.

BioSphere Medical, Inc. is a new, therapeutic device company that has pioneered the use of microscopic spheres to treat tumors and vascular disease by inhibiting
blood flow, a procedure known as embolization.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
5	I tend to agree with you Ruell. The thing I really like about it is they are f	Bill on the Hill	-	8/27/1999
4	Bill, we got the 100k day you asked for. Hopefully you stashed a few shares in	ruey220	-	8/26/1999
3	A very nice 1/4 point move on small volume Friday. What if they did a 100k sha	Bill on the Hill	-	8/14/1999
2	I am looking into the company. Thanks for starting the board.	Bill on the Hill	-	8/5/1999
1	This board will start getting some messages as soon as FDA approves the drug.	ruey220	-	8/5/1999

Go to reply# or date (mm/dd/yy):